JP2016520636A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520636A5
JP2016520636A5 JP2016517274A JP2016517274A JP2016520636A5 JP 2016520636 A5 JP2016520636 A5 JP 2016520636A5 JP 2016517274 A JP2016517274 A JP 2016517274A JP 2016517274 A JP2016517274 A JP 2016517274A JP 2016520636 A5 JP2016520636 A5 JP 2016520636A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
phenyl
acceptable salt
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016517274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520636A (ja
JP6396438B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/061501 external-priority patent/WO2014195322A1/en
Publication of JP2016520636A publication Critical patent/JP2016520636A/ja
Publication of JP2016520636A5 publication Critical patent/JP2016520636A5/ja
Application granted granted Critical
Publication of JP6396438B2 publication Critical patent/JP6396438B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016517274A 2013-06-04 2014-06-03 トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 Expired - Fee Related JP6396438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350684 2013-06-04
SE1350684-5 2013-06-04
PCT/EP2014/061501 WO2014195322A1 (en) 2013-06-04 2014-06-03 Triazole compounds and their use as gamma secretase modulators

Publications (3)

Publication Number Publication Date
JP2016520636A JP2016520636A (ja) 2016-07-14
JP2016520636A5 true JP2016520636A5 (enExample) 2017-06-01
JP6396438B2 JP6396438B2 (ja) 2018-09-26

Family

ID=50896282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517274A Expired - Fee Related JP6396438B2 (ja) 2013-06-04 2014-06-03 トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用

Country Status (7)

Country Link
US (1) US9718805B2 (enExample)
EP (1) EP3004080B1 (enExample)
JP (1) JP6396438B2 (enExample)
CN (1) CN105263922B (enExample)
DK (1) DK3004080T3 (enExample)
ES (1) ES2701810T3 (enExample)
WO (1) WO2014195322A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US10576125B2 (en) 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
KR20200045446A (ko) * 2017-06-05 2020-05-04 케이스 웨스턴 리저브 유니버시티 알츠하이머병의 치료를 위한 조성물 및 방법
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
CN121202886A (zh) * 2024-06-26 2025-12-26 浙江养生堂天然药物研究所有限公司 杂环类化合物及其用途
WO2026146201A1 (en) 2025-01-03 2026-07-09 AlzeCure Pharma AB New compounds and uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030312A1 (it) 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
JP4769718B2 (ja) 2003-08-07 2011-09-07 メルク シャープ エンド ドーム リミテッド アルツハイマー病及び関連症状の治療
WO2005054193A1 (en) 2003-12-03 2005-06-16 Merck & Co. Inc. 1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment for alzheimer's disease and related conditions
EP2261218B1 (en) 2004-05-26 2013-04-03 Eisai R&D Management Co., Ltd. Imidazole compound for use as an intermediate in the production of cinnamide compounds
CA2649996A1 (en) 2006-04-26 2007-11-08 Merck Sharp & Dohme Limited Piperidines and related compounds for treatment of alzheimer's disease
EP2019093A4 (en) 2006-05-19 2011-02-23 Eisai R&D Man Co Ltd CINEMA ACID AMID DERIVATIVE FROM THE UREA TYPE
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
US8252803B2 (en) 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
CA2695543A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
CN101848897A (zh) * 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
ATE535515T1 (de) 2008-01-11 2011-12-15 Hoffmann La Roche Modulatoren für amyloid beta
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
MX2011004680A (es) 2008-11-06 2011-05-25 Astrazeneca Ab Moduladores de beta amiloide.
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
WO2011006903A1 (en) 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
PH12012501381A1 (en) 2010-01-15 2012-10-22 Janssen Pharmaceuticals Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production

Similar Documents

Publication Publication Date Title
JP2016520635A5 (enExample)
RU2017114355A (ru) Производные нафтиридина в качестве антагонистов альфа v бета 6 интегрина для лечения, в частности, фиброзных заболеваний
JP2012508734A5 (enExample)
JP2017528504A5 (enExample)
JP2016516043A5 (enExample)
JP2014513110A5 (enExample)
JP2009542716A5 (enExample)
JO3754B1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
JP2017528503A5 (enExample)
JP2017528506A5 (enExample)
MY198769A (en) Substituted heterocyclic derivatives as cdk inhibitors
JP2019500352A5 (enExample)
JP2016538313A5 (enExample)
HRP20120969T1 (hr) Spoj azola
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
JP2016522835A5 (enExample)
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
SI3050882T1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
ME01462B (me) Vinilindazolilna jedinjenja"
CL2008003181A1 (es) Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma.
CA2921436C (en) Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
JP2018534286A5 (enExample)
JP2016513696A5 (enExample)
JP2020510046A5 (enExample)
JP2015522592A5 (enExample)